EUCTR2015-000233-73-FI进行中（未招募）不适用
HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME: PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Anginal Presentation
- •Patients of either gender who enter the hospital with prolonged or repetitive chest pain together with clearly documented ST- T wave changes indicating either unstable angina, NSTEMI or STEMI. All patients must have anginal symptoms suggestive of cardiac ischemia with one of the clinical presentations which are given in research plan
- •2 ECG Criteria (given in research plan; patient must have at least one)
- •3 Biochemical markers of myocardial damage
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1) Hypersensitivity to HCQ
- •2) Porfyria
- •3) Rheumatoid arthritis or other rheumatic disease
- •4) Retinopathy of any cause, or other eye diseases that could worsen by the use of HCQ
- •5) Significant neuropathy of any cause
- •6) Cardiomyopathy (dignosed before the onset of index hospitalization .i.e heart failure due to index myocardial infarction is not exclusion criteria)
- •7) Muscle disease (that could worsen by the use of HCQ)
- •8) Psoriasis
- •9) Any other disease or reason why investigator deems the patient not suitable for the study
研究者
相似试验
进行中（未招募）
1 期
Hydroxychloroquine in ANCA vasculitisThe term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and jointsMedDRA version: 20.0Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2018-001268-40-GBGuy's and St. Thomas' NHS Foundation Trust76
进行中（未招募）
1 期
Hydroxychloroquine for the treatment of mild COVID-19 diseaseAcute coronavirus disease 2019MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001512-26-DEniversitätsklinikum Tübingen2,700
进行中（未招募）
1 期
HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d’aggravation secondaire : étude prospective multicentrique randomisée en double aveuglePatient atteint du Covid-19EUCTR2020-001271-33-FRCHU Angers1,300
进行中（未招募）
1 期
Medication for prevention of Corona-virus for Danish nursing home residentsHealthy volunteer (Prophylaxis for COVID-19)MedDRA version: 20.0Level: PTClassification code 10049087Term: Antiviral prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001363-85-DKOdense University Hospital206
终止
2 期
Hydroxychloroquine for the Treatment of Mild COVID-19 DiseaseCOVID-19NCT04340544University Hospital Tuebingen17